Proteomic biomarker discovery for the monogenic disease cystic fibrosis

Expert Review of Proteomics

Volumn 4, Issue 2, 2007, Pages 199-209

  Penque, Deborah ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

2DE; CF modifier gene; CFTR; CFTR binding partner; Chronic lung disease biomarker; Cystic fibrosis; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 23; SYNTAXIN 1; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BIOINFORMATICS; CYSTIC FIBROSIS; DISEASE COURSE; GEL ELECTROPHORESIS; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOME; HUMAN; LUNG INSUFFICIENCY; MASS SPECTROMETRY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; CYSTIC FIBROSIS; HUMANS; PROTEOME; PROTEOMICS;

EID: 34247177900     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.2.199     Document Type: Review

References (89)

1. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
2. Wilkins MR, Sanchez JC, Gooley AA et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13, 19-50 (1996).
3. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066-1073 (1989).
4. Davis PB. Cystic fibrosis since 1938. Am. J. Respir. Crit. Care Med. 173(5), 475-482 (2006). •• Provides an informative broad overview about cystic fibrosis (CF).
5. Riordan JR. Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67, 701-718 (2005). •• Overview focused on CF transmembrane conductance regulator protein function and dysfunction.
6. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. North Am. 84(3), 597-607 (2000). • Overview of the complex genotype-phenotype correlation in CF.
7. Bernhardt J. Defining the proteome. Genome Biol. 6(12), 360 (2005).
8. Conrads TP, Hood BL, Petricoin EF III, Liotta LA, Veenstra TD. Cancer proteomics: many technologies, one goal. Expert Rev. Proteomics 2(5), 693-703 (2005).
9. Miklos GL, Maleszka R. Integrating molecular medicine with functional proteomics: realities and expectations. Proteomics 1(1), 30-41 (2001).
10. Speers AE, Cravatt BF. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11(4), 535-546 (2004).
11. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685 (2004).
12. Roxo-Rosa M, Davezac N, Bensalem N et al. Proteomics techniques for cystic fibrosis research. J. Cyst. Fibros 3(Suppl. 2), 85-89 (2004).
13. Drews O, Gorg A. DynaProt 2D: an advanced proteomic database for dynamic online access to proteomes and two-dimensional electrophoresis gels. Nucleic Acids Res. 33(Database issue), D583-D587 (2005).
14. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003). •• Describes the development and application of different mass spectrometers.
15. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl Acad. Sci. USA 97(17), 9390-9395 (2000).
16. Roe MR, Griffin TJ. Gel-free mass spectrometry-based high throughput proteomics: tools for studying biological response of proteins and proteomes. Proteomics 6(17), 4678-4687 (2006).
17. Qian WJ, Jacobs JM, Liu T, Camp DG, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 5(10), 1727-1744 (2006).
18. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1(5), 376-386 (2002).
19. Gygi SP, Rist B, Griffin TJ, Eng J, Aebersold R. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome Res. 1(1), 47-54 (2002).
20. Shadforth IP, Dunkley TP, Lilley KS, Bessant C. i-Tracker: for quantitative proteomics using iTRAQ™. BMC Genomics 6, 145 (2005).
21. Staes A, Demol H, Van Damme J, Martens L, Vandekerckhove J, Gevaert K. Global differential non-gel proteomics by quantitative and stable labeling of tryptic peptides with oxygen-18. J. Proteome Res. 3(4), 786-791 (2004).
22. Adam GC, Sorensen EJ, Cravatt BF. Chemical strategies for functional proteomics. Mol. Cell. Proteomics 1(10), 781-790 (2002).
23. Saghatelian A, Cravatt BF. Assignment of protein function in the postgenomic era. Nat. Chem. Biol. 1(3), 130-142 (2005).
24. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol. Res. Pract. 200(2), 83-94 (2004).
25. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDITOF mass spectrometry. Trends Pharmacol. Sci. 27(5), 251-259 (2006).
26. Becker KF, Metzger V, Hipp S, Hofler H. Clinical proteomics: new trends for protein microarrays. Curr. Med. Chem. 13(15), 1831-1837 (2006).
27. Sobek J, Bartscherer K, Jacob A, Hoheisel JD, Angenendt P. Microarray technology as a universal tool for high-throughput analysis of biological systems. Comb. Chem. High Throughput Screen. 9(5), 365-380 (2006).
28. Koopmann JO, Blackburn J. High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays. Rapid Commun. Mass Spectrom. 17(5), 455-462 (2003).
29. Chaurand P, Cornett DS, Caprioli RM. Molecular imaging of thin mammalian tissue sections by mass spectrometry. Curr. Opin. Biotechnol. 17(4), 431-436 (2006).
30. Crockett DK, Lin Z, Vaughn CP, Lim MS, Elenitoba-Johnson KS. Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab. Invest. 85(11), 1405-1415 (2005).
31. Hood BL, Darfler MM, Guiel TG et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol. Cell. Proteomics 4(11), 1741-1753 (2005).
32. Palmer-Toy DE, Krastins B, Sarracino DA, Nadol JB Jr, Merchant SN. Efficient method for the proteomic analysis of fixed and embedded tissues. J. Proteome Res. 4(6), 2404-2411 (2005).
33. Palagi PM, Hernandez P, Walther D, Appel RD. Proteome informatics I: Bioinformatics tools for processing experimental data. Proteomics 6(20), 5435-5444 (2006).
34. Lisacek F, Cohen-Boulakia S, Appel RD. Proteome informatics II: bioinformatics for comparative proteomics. Proteomics 6(23), 6380 (2006). •• Attempts to cover the most recent bioinformatics initiatives directed towards representing, storing, displaying and processing protein-related data suited to undertake comparative proteomics studies.
35. Zolg W. The proteomic search for diagnostic biomarkers: lost in translation? Mol. Cell. Proteomics 5(10), 1720-1726 (2006). • Highlights important considerations in biomarker discovery phase, such as making selections, setting priorities, facing the complexity of samples and validation strategies, among others.
36. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23(1), 146-158 (2004).
37. Tarran R. Regulation of airway surface liquid volume and mucus transport by active ion transport. Proc. Am. Thorac. Soc. 1(1), 42-46 (2004).
38. Moeller A, Horak F Jr, Lane C et al. Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis. Thorax 61(6), 514-520 (2006).
39. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J. Clin. Invest. 102(6), 1200-1207 (1998).
40. Poschet JF, Boucher JC, Tatterson L, Skidmore J, Van Dyke RW, Deretic V. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc. Natl Acad. Sci. USA 98(24), 13972-13977 (2001).
41. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc. Natl Acad. Sci. USA 92(7), 3019-3023 (1995).
42. Bryan R, Kube D, Perez A, Davis P, Prince A. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am. J. Respir. Cell Mol. Biol. 19(2), 269-277 (1998).
43. Pier GB, Grout M, Zaidi TS et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271(5245), 64-67 (1996).
44. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151(4), 1075-1082 (1995).
45. Zahm JM, Gaillard D, Dupuit F et al. Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice. Am. J. Physiol. 272(3 Pt 1), C853-C859 (1997).
46. Venaille TJ, Ryan G, Robinson BW. Epithelial cell damage is induced by neutrophil-derived, not Pseudomonas-derived, proteases in cystic fibrosis sputum. Respir. Med. 92(2), 233-240 (1998).
47. Hull J, Vervaart P, Grimwood K, Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 52(6), 557-560 (1997).
48. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration 67(2), 117-133 (2000).
49. Kristidis P, Bozon D, Corey M et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 50(6), 1178-1184 (1992).
50. Bronsveld I, Mekus F, Bijman J et al. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J. Clin. Invest. 108(11), 1705-1715 (2001).
51. Cutting GR. Modifier genetics: cystic fibrosis. Annu. Rev. Genomics Hum. Genet. 6, 237-260 (2005). •• Details the current state-of-the-art in CF and CF-modifier genes
52. Vankeerberghen A, Cuppens H, Cassiman JJ. The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions. J. Cyst. Fibros 1(1), 13-29 (2002).
53. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95(7), 1005-1015 (1998).
54. Mall M, Bleich M, Greger R, Schreiber R, Kunzelmann K. The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J. Clin. Invest. 102(1), 15-21 (1998).
55. + absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10(5), 487-493 (2004).
56. + conductance, and cystic fibrosis phenotype. Pediatr. Pulmonol. 27(4), 251-259 (1999).
57. Eggermont J. Calcium-activated chloride channels: (un)known, (un)loved? Proc. Am. Thorac. Soc. 1(1), 22-27 (2004).
58. Machen TE. Innate immune response in CF airway epithelia: hyperinflammatory? Am. J. Physiol. Cell Physiol. 291(2), C218-C230 (2006).
59. Li C, Naren AP. Macromolecular complexes of cystic fibrosis transmembrane conductance regulator and its interacting partners. Pharmacol. Ther. 108(2), 208-223 (2005).
60. Mehta A. CFTR: More than just a chloride channel. Pediatr. Pulmonol. 39(4), 292-298 (2005).
61. Sun F, Zhang R, Gong X, Geng X, Drain PF, Frizzell RA. Derlin-1 promotes the efficient degradation of CFTR and CFTR folding mutants. J. Biol. Chem. 281(48), 36856-36863 (2006).
62. Vij N, Fang S, Zeitlin PL. Selective inhibition of endoplasmic reticulum-associated degradation rescues ΔF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 281(25), 17369-17378 (2006).
63. Naren AP, Kirk KL. CFTR chloride channels: binding partners and regulatory networks. News Physiol. Sci. 15, 57-61 (2000).
64. Scholte BJ, Davidson DJ, Wilke M, De Jonge HR. Animal models of cystic fibrosis. J. Cyst. Fibros 3(Suppl. 2), 183-190 (2004).
65. Gruenert DC, Willems M, Cassiman JJ, Frizzell RA. Established cell lines used in cystic fibrosis research. J. Cyst. Fibros 3(Suppl. 2), 191-196 (2004).
66. Penque D, Mendes F, Beck S et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab. Invest. 80(6), 857-868 (2000).
67. Danel C, Erzurum SC, McElvaney NG, Crystal RG. Quantitative assessment of epithelial and inflammatory cell populations in large airways of normals and individuals with cystic fibrosis. Am. J. Respir. Crit. Care Med. 153(1), 362-368 (1996).
68. Carvalho-Oliveira I, Efthymiadou A, Malho R et al. CFTR localization in native airway cells and cell lines expressing wild-type or F508del-CFTR by a panel of different antibodies. J. Histochem. Cytochem. 52(2), 193-203 (2004).
69. Roxo-Rosa M, da Costa G, Luider TM et al. Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease. Proteomics 6(7), 2314-2325 (2006).
70. Sloane AJ, Lindner RA, Prasad SS et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am. J. Respir. Crit. Care Med. 172(11), 1416-1426 (2005).
71. Noel-Georis I, Bernard A, Falmagne P, Wattiez R. Proteomics as the tool to search for lung disease markers in bronchoalveolar lavage. Dis. Markers 17(4), 271-284 (2001).
72. Neumann M, von Bredow C, Ratjen F, Griese M. Bronchoalveolar lavage protein patterns in children with malignancies, immunosuppression, fever and pulmonary infiltrates. Proteomics 2(6), 683-689 (2002).
73. Plymoth A, Lofdahl CG, Ekberg-Jansson A et al. Human bronchoalveolar lavage: biofluid analysis with special emphasis on sample preparation. Proteomics 3(6), 962-972 (2003).
74. von Bredow C, Birrer P, Griese M. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur. Respir. J. 17(4), 716-722 (2001).
75. Bai Y, Galetskiy D, Damoc E et al. High-resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 4(8), 2300-2309 (2004).
76. Veenstra TD, Conrads TP. Serum protein fingerprinting. Curr. Opin. Mol. Ther. 5(6), 584-593 (2003).
77. Villar-Garea A, Griese M, Imhof A. Biomarker discovery from body fluids using mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2006) (Epub ahead of print).
78. Pedersen SK, Sloane AJ, Prasad SS et al. An immunoproteomic approach for identification of clinical biomarkers for monitoring disease: application to cystic fibrosis. Mol. Cell. Proteomics 4(8), 1052-1060 (2005).
79. Fehniger TE, Sato-Folatre JG, Malmstrom J et al. Exploring the context of the lung proteome within the airway mucosa following allergen challenge. J. Proteome Res. 3(2), 307-320 (2004).
80. Roh GS, Shin Y, Seo SW et al. Proteome analysis of differential protein expression in allergen-induced asthmatic mice lung after dexamethasone treatment. Proteomics 4(11), 3318-3327 (2004).
81. Houtman R, Krijgsveld J, Kool M et al. Lung proteome alterations in a mouse model for nonallergic asthma. Proteomics 3(10), 2008-2018 (2003).
82. Carvalho-Oliveira I, Luider TM, Demmers J, Penque D, Scholte BJ. Identification of proteins by mass spectrometry on laser-dissected cells from mouse proximal bronchial epithelium. Mol. Cell. Proteomics 4(8 Suppl. 1), S142 (2005).
83. Pollard HB, Ji XD, Jozwik C, Jacobowitz DM. High abundance protein profiling of cystic fibrosis lung epithelial cells. Proteomics 5(8), 2210-2226 (2005).
84. Pollard HB, Eidelman O, Jozwik C et al. De novo biosynthetic profiling of high abundance proteins in cystic fibrosis lung epithelial cells. Mol. Cell Proteomics 5(9), 1628-1637 (2006).
85. Davezac N, Tondelier D, Lipecka J et al. Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/ΔF508-CFTR to the plasma membrane. Proteomics 4(12), 3833-3844 (2004).
86. Kitano H. Systems biology: a brief overview. Science 295(5560), 1662-1664 (2002). • Highlights the importance of systems biology for the structure and dynamics examination of cellular and organismal function.
87. Cystic Fibrosis Mutation Database www.genet.sickkids.on.ca/cftr/app
88. Human Proteome Organisation www.hupo.org
89. European Proteomics Association www.eupa.org